Histone deacetylase 9 (HDAC9), also known as HDAC7A or HDAC7, is a class IIa histone deacetylase that plays critical roles in epigenetic regulation, transcriptional repression, and cellular differentiation. HDAC9 has emerged as a significant player in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), where it regulates gene expression programs controlling neuronal survival, synaptic plasticity, and neuroinflammation. This protein represents an important therapeutic target given its druggable enzymatic activity and disease-modifying potential 1.
:: infobox .infobox-protein
| Protein Name | HDAC9 (Histone Deacetylase 9) |
| Gene | HDAC9 |
| UniProt | Q9UKV0 |
| Molecular Weight | ~110 kDa (full-length isoform) |
| Subcellular Localization | Nucleus, cytoplasm (signal-dependent shuttling) |
| Protein Family | Class IIa histone deacetylase family |
| Tissue Expression | Brain (neurons, glia), heart, skeletal muscle |
::
HDAC9 belongs to the class IIa HDAC family, which includes HDAC4, HDAC5, HDAC7, and HDAC9. These proteins are characterized by N-terminal regulatory domains that mediate signal-dependent nuclear-cytoplasmic shuttling and their ability to regulate tissue-specific gene expression programs 2.
¶ Structure and Domain Architecture
HDAC9 possesses a characteristic class IIa HDAC structure:
¶ N-Terminal Regulatory Domain (Amino Acids 1-150)
The N-terminal region contains:
- MEF2-binding domain: Recognizes MADS-box transcription factors (MEF2A-D)
- NLS (Nuclear Localization Signal): Basic region for nuclear import
- Phosphorylation sites: Serine residues regulated by kinases (CaMK, PKD)
- 14-3-3 binding motifs: Mediate cytoplasmic sequestration
This regulatory domain allows HDAC9 to function as a signal-responsive transcriptional co-repressor. Phosphorylation by calcium/calmodulin-dependent kinase (CaMK) creates 14-3-3 binding sites, promoting HDAC9 export to the cytoplasm 3.
¶ Catalytic Core Domain (Amino Acids 150-500)
The central catalytic domain contains:
- Zinc-binding pocket: Zn²⁺ ion required for deacetylase activity
- Active site residues: His976, Asp993, Cys1015 (human numbering)
- Loop structures: Confer substrate specificity
- HDAC inhibitor binding site: Target for vorinostat, entinostat (MS-275)
The catalytic domain shares homology with other class I and IIa HDACs but has distinct substrate preferences, including non-histone proteins 4.
- Nuclear export signal (NES): Leucine-rich motif for CRM1-mediated export
- Dimerization interface: Enables HDAC9 homodimer and heterodimer formation
- Alternative splicing sites: Generates multiple isoforms with distinct functions
HDAC9 produces multiple alternatively spliced isoforms:
- HDAC9-A: Full-length isoform (669 aa), nuclear localized
- HDAC9-B: Lacks N-terminal MEF2-binding domain
- HDAC9-C: Alternative N-terminus, muscle-specific
- HDAC9-7: Lacks catalytic domain, dominant-negative function
- HDAC9a/HDAC9b: Brain-specific variants
Isoform expression is tissue-specific and dynamically regulated during development and disease. Brain isoforms include HDAC9a and HDAC9b, which differ in their N-terminal sequences and cellular localization.
HDAC9 regulates gene expression through:
- Histone deacetylation: Removes acetyl groups from lysine residues on histone H3/H4
- Chromatin condensation: Acetylated histones → deacetylated → compact chromatin
- Transcription factor interaction: Binds MEF2, REST, and other TFs as co-repressor
- CoREST complex recruitment: Mediates gene silencing through multi-protein complexes
During neural development, HDAC9 controls:
- Neuronal differentiation: Repression of proliferation genes in post-mitotic neurons
- Synaptogenesis: Regulation of synaptic protein expression
- Axon guidance: MEF2-dependent transcription of guidance cues
- Myelination: Oligodendrocyte differentiation and myelination genes 5
HDAC9 regulates synaptic plasticity through:
- Activity-dependent transcription: MEF2-driven immediate-early gene expression
- Synaptic scaling: Homeostatic adjustments to neuronal activity
- LTP/LTD: Histone acetylation states at plasticity-related genes
- Dendritic spine remodeling: Control of spine morphology
HDAC9 contributes to tau pathology through multiple mechanisms:
- Tau phosphorylation regulation: HDAC9 deacetylates tau at Lys residues
- GSK-3β expression: Represses negative regulators of tau kinase
- Tau aggregation: Alters acetylation patterns affecting aggregation
- Tau turnover: Modulates autophagy and proteasomal degradation
In response to Aβ:
- Synaptic gene repression: HDAC9 overactivity silences synaptic genes
- Memory consolidation: Impedes CREB-mediated transcription
- Neuronal vulnerability: Reduces survival gene expression
HDAC9 inhibition strategies for AD:
- HDAC inhibitors: Vorinostat, entinostat (MS-275) in clinical trials
- Isoform-selective inhibitors: Targeting class IIa vs class I HDACs
- MEF2 activators: Small molecules enhancing MEF2-HDAC9 dissociation
- Gene therapy: AAV-delivered HDAC9 shRNA 6
HDAC9 affects PD through:
- α-Synuclein regulation: Controls expression of SNCA gene
- Mitochondrial gene expression: Alters PGC-1α pathway genes
- Oxidative stress response: Modulates antioxidant gene programs
- Neuroinflammation: Regulates glial inflammatory responses
- Elevated HDAC9 activity in substantia nigra of PD patients
- MEF2 dysfunction contributes to dopaminergic neuron loss
- HDAC9 protects against 6-OHDA and MPTP toxicity in models
HDAC9 represses PGC-1α (PPARGC1A), a master regulator of mitochondrial biogenesis:
- Reduced PGC-1α leads to mitochondrial dysfunction
- Dopaminergic neurons are particularly vulnerable
- Enhancing PGC-1α protects against PD models 7
In ALS, HDAC9 interacts with TDP-43 pathology:
- Aggregation: TDP-43 inclusions sequester HDAC9
- Transcriptional dysregulation: Loss of HDAC9 function alters gene expression
- Spliceopathy: HDAC9 regulates splicing factors affected in ALS
- Axonal transport: Alters expression of transport protein genes
HDAC9 mechanisms in motor neuron disease:
- Synaptic gene repression: Impedes neuromuscular junction maintenance
- Metabolic dysfunction: Alters energy homeostasis genes
- Glial contribution: Regulates astrocyte and microglial responses
HDAC9 modulates neuroinflammation through:
- Pro-inflammatory gene repression: HDAC9 restrains excessive inflammation
- TLR signaling: Modulates innate immune responses
- Cytokine expression: Controls IL-1β, TNF-α, IL-6 transcription
- Reactive astrogliosis: Regulates GFAP and other astrocyte markers
- Neurotrophic support: Modulates BDNF and GDNF expression
- Blood-brain barrier: Influences endothelial cell interactions
HDAC9 mediates histone deacetylation:
- H3K9ac → H3K9ac: Chromatin silencing
- H3K14ac → H3K14ac: Transcriptional repression
- H4K5ac → H4K5ac: Long-term gene silencing
HDAC9 also deacetylates non-histone proteins:
- p53: Tumor suppressor regulation
- STAT3: Cytokine signaling modulation
- NF-κB: Inflammatory response control
- MEF2: Activity-dependent regulation
HDAC9 responds to calcium signals:
- Ca²⁺ influx activates CaMK
- CaMK phosphorylates HDAC9
- 14-3-3 binding promotes nuclear export
- MEF2 target genes are derepressed
- PKA phosphorylation affects HDAC9 activity
- cAMP elevation promotes HDAC9 nuclear export
- Crosstalk with calcium signaling
- p38 MAPK: Phosphorylates HDAC9 under stress
- JNK: Regulates HDAC9 nuclear import
- ERK: Controls HDAC9 protein stability
HDAC9 integrates metabolic signals:
- AMPK phosphorylates HDAC9 during energy deficit
- MEF2 activity links metabolism to gene expression
- Mitochondrial function affects HDAC9 localization
- SREBP target genes regulated by HDAC9
- Cholesterol levels affect HDAC9 activity
- Fatty acid oxidation influences neuronal survival
- Controls MEF2-dependent gene expression
- Regulates synaptic plasticity genes
- Modulates neuronal survival pathways
- Different isoform expression than neurons
- Regulates inflammatory responses
- Controls glial cell differentiation
| Interacting Protein |
Interaction Type |
Functional Outcome |
| MEF2A/D |
Direct (DNA-binding) |
Transcriptional repression |
| REST/CoREST |
Complex recruitment |
Neuronal gene silencing |
| HDAC3 |
Heterodimer |
Corepressor complex |
| HDAC5 |
Heterodimer |
Nuclear export regulation |
| 14-3-3 proteins |
Phospho-dependent |
Cytoplasmic sequestration |
| CaMK1D |
Phosphorylation |
Activity modulation |
| PKD1 |
Phosphorylation |
Nuclear export |
| SUV39H1 |
Chromatin modifier |
Heterochromatin formation |
| MTA1 |
Complex |
NuRD complex recruitment |
| MBD |
Methyl-CpG binding |
Epigenetic reader crosstalk |
| BCL6 |
Co-repressor |
Transcriptional repression |
| CTBP |
Co-repressor |
Chromatin remodeling |
- Vorinostat (SAHA): Pan-HDAC inhibitor, approved for T-cell lymphoma
- Entinostat (MS-275): Class I-selective, in CNS trials 8
- Tefinostat: Tumor-selective, prodrug approach
- Panobinostat: In clinical trials for various indications
- Isoform-selective compounds: RGFP966 (HDAC3 selective)
- HDAC9-specific antibodies: Neutralizing approaches
- Targeted delivery: Lipid nanoparticle CNS penetration
- Gene therapy: CRISPR activation of beneficial HDAC9 functions
- Pan-HDAC inhibitors cause side effects
- Class IIa selectivity is challenging
- Blood-brain barrier penetration needed
- Long-term treatment effects unknown
- Hdac9⁻/⁻ mice: Viable with cardiac defects, enhanced learning 9
- Transgenic overexpression: HDAC9tg mice show memory deficits
- Conditional knockouts: Brain-specific deletion improves cognition
- Alzheimer's models: HDAC9 deletion reduces amyloid pathology
¶ Biomarkers and Diagnostics
HDAC9 as a biomarker:
- CSF HDAC9 activity: Elevated in AD and PD
- Blood HDAC9 mRNA: Potential peripheral marker
- PET ligands: HDAC-targeting radiotracers in development
- Histone acetylation ratios: Peripheral blood mononuclear cells
HDAC9 polymorphisms associated with:
- Alzheimer's disease: rs12533828 modifies risk
- Parkinson's disease: rs12602993 affects progression
- Schizophrenia: Rare variants in cases
- Cardiovascular disease: rs2106261
- Class I (HDAC1,2,3): Nuclear, ubiquitous
- Class IIa (HDAC4,5,7,9): Signal-dependent shuttling
- Different tissue distribution
- Unique isoform patterns
- Non-redundant functions
HDAC9 represents a critical epigenetic regulator in neurodegenerative diseases, with roles in tau pathology, α-synuclein toxicity, and neuroinflammation. Its druggable enzymatic activity makes it an attractive therapeutic target, though isoform selectivity remains important to avoid class-wide side effects. Further research is needed to develop brain-penetrant HDAC9-specific inhibitors and understand the cell-type-specific functions of this complex protein 10.